CareLit Fachartikel

Efficacy and safety of risankizumab in patients with moderate to severe crohn’s disease: Results from the one-year SEQUENCE open-label Long-term extension

L Peyrin-Biroulet, R Atreya, S Danese, J O Lindsay, J C Chapman, T Anschutz, X Huang, J Zambrano, A Platt, N Joshi, R K Cross · Zeitschrift für Gastroenterologie · 2025 · Heft 08 · S. e418-e419

Dokument
953736
CareLit-ID
Jahr
2025
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Zeitschrift für Gastroenterologie
Autor:innen
L Peyrin-Biroulet, R Atreya, S Danese, J O Lindsay, J C Chapman, T Anschutz, X Huang, J Zambrano, A Platt, N Joshi, R K Cross
Ausgabe
Heft 08 / 2025
Jahrgang 63
Seiten
e418-e419
Erschienen: 2025-09-01 00:00:00
ISSN
0044-2771
DOI
10.1055/s-0045-1810726

Zusammenfassung

Efficacy and safety of risankizumab in patients with moderate to severe crohn’s disease: Results from the one-year SEQUENCE open-label Long-term extension

Schlagworte

Efficacy Safety Risankizumab Patients Moderate Severe Crohn Disease Results One-Year Sequence Open-Label Zeitschrift für Gastroenterologie